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Summary We have shown that doxorubicin entrapped in cardiolipin liposomes retain antitumour efficacy in
mice but had diminished cardiac uptake and cardiotoxicity. Such liposomes are preferentially taken up by
spleen. In a previous study we showed that a single dose of liposomal doxorubicin is not more toxic than free
doxorubicin with regard to immunologic parameters including generation of cytotoxicity for histo-
compatibility alloantigens and mitogenic responsiveness. In the present study, we have explored clinically
relevant multiple dosing at weekly intervals, 2, 3, or 4 times. Again, despite splenic localization of liposomal
doxorubicin, the depressive effect on these immunological parameters is not greater than the effect of free
drug, and, in addition, the damage is repaired earlier.
Anthracyclines such as doxorubicin and
daunorubicin are active agents against a wide
variety of human neoplasms (Bonadonna et al.,
1970, Haanen & Hillen, 1975; Oldham & Pomeroy,
1972; Middleman et al., 1971). However, effective
clinical use of these compounds has been
compromised by a serious dose-related cardio-
myopathy (Rinehart et al., 1974; Chabner & Myers,
1982). Juliano et al. (1978a, b, 1983) and
Gregoriadis et al. (1977, 1982) have demonstrated
that liposomes can serve as effective carriers of
anticancer drugs by altering the pharmacokinetics
and localization of these agents in vivo. Sub-
sequently, the use of liposomes as carriers of doxo-
rubicin has been demonstrated to offer important
advantages with regard to the attenuation of the
dose-dependent cardiotoxicity. This effect has been
shown in rodents (Rahman et al., 1982; 1984; 1985;
Olson et al., 1982; Forssen & Tokes, 1979; Gabizon
et al., 1982; Parker et al., 1981) and is apparently at
least partly attributable to the reduced uptake of
doxorubicin in cardiac tissue when it is adminis-
tered entrapped in liposomes. Recently, we have
demonstrated that doxorubicin entrapped in cardio-
lipin liposomes and administered over a long period
affords complete protection from drug-induced
cardiotoxicity in beagle dogs (Herman et al., 1983).
This protection is correlated with enhanced thera-
peutic efficacy and decreased mortality (Rahman et
al., 1986a).
Doxorubicin and related compounds are shown
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to be immunosuppressive. They are known to affect
antibody production and various aspects of cellular
immunity (Pfeiffer & Bosmann, 1982; Santoni et al.,
1980). In our previous studies, we have
demonstrated preferential uptake of liposomal
doxorubicin in spleen as compared to uptake of
free drug. We hypothesized that this exaggrrated
concentration of drug in spleen might affect
immunity adversely. Recently we tested the
proposition that liposomal doxorubicin suppresses
antigen specific cellular cytotoxicity and
proliferative responses to the mitogens concanavalin
A and lipopolysaccharide. We found unexpectedly
that the suppression is altered in timing but not in
magnitude and it is of shorter duration than
following administration of free doxorubicin
(Rahman et al., 1986b). In this report, we have
examined immunologic consequences of
administration of multiple doses of free doxorubicin
and doxorubicin entrapped in cardiolipin liposomes,
a mode of administration which resembles more
closely the clinical setting.
Materials and methods
Doxorubicin was kindly provided by the
Developmental Therapeutics Program, National
Cancer Institute, Bethesda, Maryland, USA.
Phosphatidyl choline, cardiolipin, cholesterol and
stearylamine were purchased from Sigma Chemicals
Co. (St. Louis, Mo., USA). The lipids were tested
for purity by thin-layer chromatography on silica
gel with the solvent system chloroform/
methanol/water 70:30:5 (by volume) and phos-
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phatidyl choline, cardiolipin, cholesterol and steary-
lamine were found to be 99%, 98%, 99% and 90%
pure respectively. Doxorubicin was encapsulated
into liposomes by mixing 39.35 imol of drug in
methanol with 19.65 imol cardiolipin. The mixture
was evaporated to dryness under N2* To this dried
mixture were then added lOOpmol phosphatidyl
choline, 68.4,umol cholesterol and 38.9,umol
stearylamine. The mixture was stirred gently to
achieve a homogeneous solution and evaporated to
dryness under N2* The dried mixture was
resuspended in 1Oml 0.01 M phosphate buffer with
0.85% NaCI, pH 7.4 (PBS). After a half-hour
swelling, the liposomes were stirred for 15min
followed by sonication (Heat System, W-220F)
under N2 in a fixed-temperature bath at 37°C for
90min. The non-entrapped doxorubicin was
separated from liposome-encapsulated drug by
extensive dialysis against 0.001 M phosphate buffer
with 0.85% NaCl, pH 7.4 at 40C over a period of
20h with at least two changes of buffer solution.
The percentage entrapment of doxorubicin in
cardiolipin liposomes was determined by fluor-
escence after the completion of dialysis and was
found to be 55% of the total input dose (Rahman
et al., 1985). Thus for each milligram of doxo-
rubicin administered in liposomes 13mg of lipid
needs to be administered. The size of the liposomes
as determined by electron microscopy ranged from
900 to 1,100A. Liposomes were prepared fresh each
day they were studied and were diluted with PBS to
the desired concentration of doxorubicin. These
liposomes were used to perform comparative
chronic immunotoxicity studies.
Mice
Male mice of the (BALB/c x DBA/2) F1 hybrid
strain CDF1 and weighing 20-25g were obtained
commercially from Charles River Co. (Boston,
Ma). C57BL/6J males aged 6-8 weeks were
obtained from Jackson Laboratories (Bar Harbor,
Me, USA). Mice were maintained according to the
accredited procedures in our facility and enjoyed
uniformly good health at the initiation of the
studies.
Cell lines
The murine cell lines EL-4(H-2") and P-815(H-2d)
were obtained originally from Dr. J. Wunderlich.
Both have been tested for mycoplasma and
mycoplasma free aliquots were maintained in
culture and were used as targets.
Sequence ofstudies
Free doxorubicin was administered to CDF1 mice
at a dose of 7.5mgkg-1 and at a volume of
0.02mlg-1 body weight via a lateral tail vein.
Three groups of mice were utilized and received
respectively 2, 3, or 4 doses of drug at weekly
intervals. Doxorubicin entrapped in cardiolipin
liposomes was administered at a dose of
10.5mgkg-1 i.v. and at a volume of 0.02mlg-1
body weight. Three groups of mice received
respectively 2, 3 and 4 doses of liposomal drug at
weekly intervals. Multiple i.v. injections of free
doxorubicin produce extreme venous sclerosis and
the utmost care was taken to avoid extravasation of
the drug. However, with liposomal doxorubicin
venous sclerosis following multiple injections of the
drug appears to have been substantially reduced.
Control mice received either saline or blank
liposomes with the same concentration of lipids as
used to entrap the drug. Control mice were injected
at the same schedule as drug treated mice. At days
1, 8, 15 and 22 after the last drug dose mice were
bled from the orbital sinus and blood was collected
in test tubes. Mice were then killed by cervical
dislocation, and the spleens were removed quickly
under aseptic conditions. Four mice in each
treatment group were killed at each time point.
Blood was centrifuged at 1,000r.p.m. and serum
collected for IgG levels. The spleen of each mouse
was processed for immunologic evaluation as
described below.
In vitro sensitization
The spleens isolated from mice sacrificed by
cervical dislocation were disrupted mechanically
and erythrocytes were removed with lysing buffer.
Spleen cells thus obtained were used as responders
and stimulators for in vitro generation of
cytotoxicity. Responder cells were suspended at
106ml- I in Eagle's Minimal Essential Medium
(MEM) with added mutrients, antibiotics and 10%
preselected foetal calf serum (FCS). Stimulator cells
were irradiated at 20Gy and added at 2 x 106 ml-1.
Cultures were incubated at 37°C in humidified 5%
CO2 in air for 5 days.
Assay ofcell mediated cytolysis
Targets were labelled for 1 h in 1 ml MEM
containing antibiotics and 5% FCS with 0.1 mCi
Na251Cr4 (Amersham, Arlington Heights, Ill,
USA). Targets were washed three times and plated
at 5,000/well in 200Mu round-bottom microwells in
96-well plates. Cells to be assayed for cytotoxicity
were added in appropriate concentrations to
achieve attacker-to-target ratios of 40:1, 20:1, 10:1
and 5:1. All conditions were tested in triplicate.
Releasable isotope (max) was determined by adding
O.lNHCl to targets. Spontaneous release (SR) was
determined from medium added to targets. Wells
were spun at 50g for 2min at 23°C and incubated atIMMUNOTOXICITY OF FREE AND LIPOSOME ENTRAPPED DOXORUBICIN 403
37°C in 5% CO2 in air for 4h. Plates were spun at
775g for 5min at 4°C, harvested by means of the
Titertek Supernatant Collection system (Flow
Laboratories, Rockville, Md, USA) and counted
(Beckman Gamma 4000, Fullerton, Calif., USA).
The corrected percentage lysis is (experimental-SR)/
(Max-BG), where BG is machine background. SR
was < 10% in most cases.
Calculation oflytic units and lytic activity
Lytic units were calculated with a computer
program generated by Ms. E. Phillips as previously
described (Neefe et al., 1983). In brief, straight lines
were fitted to the titration curve for percentage lysis
versus the logarithm of the attacker-to-target ratio.
Normal animals or saline-treated controls were
assumed to have a standard lytic activity
concentration of 1.0. The distance between the two
lines of the experimental values and the standard or
control values is a measure of the relative
concentration of lytic activities. The value for total
lytic activity per spleen is an arbitrary number
obtained by multiplying the concentration of lytic
activity by the number of nucleated cells in the
spleen tested.
Proliferation assays
Spleen cells obtained as above were plated in 200jp
round-bottom wells in 96-well plates at a
concentration of 5 x 105 ml-P1 quadruplicate. The
mitogens concanavalin A and lipopolysaccharide
were added to appropriate wells at concentrations
of I jgml - 1 and 10 ugml-1, respectively. Controls
with no mitogen were also plated. Plates were
incubated for 36-44h, then pulsed with 0.5pCi
[3H]-thymidine for 4h, and harvested with a
MASH II (Microbiological Associates, Rockville,
Md) onto absorbent strips. These were dried,
placed in scintillation fluid (Beta Fluor, National
Diagnostics, Somerville, NJ), and counted on a
Beckman LS7000.
Determination ofimmunoglobulins in mouse serum
Radial immunodiffusion of mouse serum was
performed injected with free doxorubicin and
doxorubicin entrapped in cardiolipin liposomes for
determination of total IgG levels. For these studies
Miles Laboratories (Elkhart, Indiana) IgG kit was
utilized. Standard IgG concentrations, 5ju each,
were applied on the immunodiffusion wells. Sera of
mice in each treated group were subsequently
applied in 5jl volumes to the remaining wells of
immunodiffusion plates and the samples were read
after 18h of incubation at room temperature. The
ring diameters of each standard applied was plotted
in a semilogarithmic graph paper and IgG levels of
various treated group sera of mice were then
directly read.
Results
The spleen cells from sacrificed mice were sensitized
in vitro to allogeneic (I-!-2") transplantation
antigens. The kinetics of this activity are shown in
Figures 1-3. The saline control was used as the
standard for generation of the lytic unit calculation
for each of the other three groups in each treatment
schedule. The activity of the saline control was
arbitrarily assumed to be 1.0 units. The animals
treated with blank liposomes showed a very definite
increase in activity in comparison with saline
control. This was most consistently observed on
day 1 (Figures 1-3). It was also seen at the other
time points and the effect was persistent even at
day 22. Animals injected with two doses of free
doxorubicin showed a marked decrease in the
capacity to mount an allospecific cytotoxic response
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Figure 1 T-cell mediated cytotoxicity against H-2b
alloantigens. Saline treated controls are used to
normalize the response as lytic units. Animals received
blank liposomes (0), free doxorubicin 7.5mgkg-
(0) or doxorubicin encapsulated in liposomes,
l0.5mgkg-l (El) every week for 2 weeks i.v.
Individual symbols represent single animals and the
lines represent the arithmetic mean response.
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Figure 2 T-cell mediated cytotoxicity against H-2'
alloantigens. Saline treated controls are used to
normalize the response as lytic units. Animals received
i.v. blank liposomes (O), free doxorubicin
7.5mgkg-1, (0) doxorubicin encapsulated in
liposomes, 10.5mgkg-' (Ol) every week for 3 weeks.
Individual symbols represent single animals and the
lines represent the arithmetic mean response.
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Figure 3 T-cell mediated cytotoxicity against H-2b
alloantigens. Saline treated controls are used to
normalize the response as lytic units. Animals received
i.v. blank liposomes (0), free doxorubicin 7.5mgkg-'
(O), doxorubicin encapsulated in liposomes
l0.Smgkg-1 (Ol), every week for 4 weeks. Individual
symbols represent single animals and the lines
represent the arithmetic mean.
on day 1 which was further depressed on day 8.
There appeared to be a gradual recovery on day 15.
However, this defect was not even fully repaired by
day 22, the last observation point. Animals treated
with doxorubicin entrapped in cardiolipin liposomes
showed maximum inhibition in cytotoxicity
response on day 8. However, the magnitude of
depression was much less than observed with free
drug and was almost fully recovered by day 15. The
cytotoxicity observed was allospecific, as seen from
the fact that syngeneic and irrelevant allogenic
targets were not killed by any of the cytotoxic
populations.
The administration of three doses of free
doxorubicin to mice caused a marked decrease in
the generation of allospecific cytotoxic response
(Figure 2). This effect was present until day 15 with
partial recovery by day 22. Similarly, mice treated
with liposomal doxorubicin demonstrated profound
decrease in cytotoxicity on day 1 and 8 with partial
recovery on day 15 and full recovery by day 22.
The same characteristics in response were observed
in mice treated with four weekly doses of
doxorubicin (Figure 3). The cytotoxicity with free
doxorubicin was more depressed on day 1, 8 and 15
with partial recovery on day 22. The liposomal
entrapped drug demonstrated maximum depression
in activity on day 8 but the decrease was almost
fully recovered on day 15.
Proliferative responses
The spleens of the animals treated with various
schedules of drug administered were tested for their
capacity to mount a proliferative response. Table I
shows the mean response of each group to the
mitogen concanavalin A. The absolute number of
counts taken up by the stimulated cells of the saline
control varies considerably from assay to assay; in
these experiments and other experiments, the test
animals were normalized to a response index by
dividing the counts by those of the saline controls.
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Table I Proliferative response indexa of treated mice for concanavalin A
Drug coursesb Day JC Day 8 Day 15 Day 22
Blank liposomes 2.12+0.84d 1.22+0.84 1.26+0.36 1.09+0.70
2 Free doxorubicin 2.33+1.09 1.07+0.28 0.83+0.34 0.90+0.53
Liposomal
doxorubicin 1.92+0.56 0.69+0.26 0.67+0.04 0.92+0.35
Blank liposomes 1.29+0.44 1.19+0.27 1.81 +0.62 1.74+ 1.07
3 Free doxorubicine 0.05+0.03 0.04+0.003 0.74+0.16 0.25+0.11
Liposomal
doxorubicin 0.16+0.01 0.53+0.01 1.10+0.44 3.04+2.68
Blank liposomes 0.40+0.19 0.65+0.38 0.72+0.01 0.78+0.20
4 Free doxorubicin 0.16+0.13 0.15+0.03 0.25+0.07 0.85+0.13
Liposomal
doxorubicin 0.33+0.23 0.67+0.51 0.67+0.10 0.82+0.17
aIndex is counts of experimental animals divided by mean counts of saline-treated control
animals; 'Number of weekly injections of indicated treatment; CDays are counted from the
time of last drug treatment; dMean proliferative response index+s.d.: 3-4 animals per group;
eItalicised values for free doxorubicin are significantly lower than liposomal drug by + test
at P<0.05.
With two doses of drug, no dramatic alteration in
response to concanavalin A was observed at any
time. This result corresponds to our previously
published result with one dose (Rahman et al.,
1986). With three and four doses marked
depression was noted on day 1 with repair
occurring by day 8-15. The depression with free
drug was more profound and repaired later.
Table II presents the proliferative response of the
treated animals with lipopolysaccharide. We
previously showed substantial and similar
depression of response with either form of drug
after one dose. Multiple dosing produced essentially
the same pattern with both forms of drug; early
depression with substantial repair by day 8-22.
Immunoglobulin levels
Total IgG levels were determined by radial
immunodiffusion assay in mice treated with three
and four weekly doses of free doxorubicin and
doxorubicin entrapped in cardiolipin liposomes and
Table II Proliferative response index of treated mice for lipopolysaccharidea
Drug coursesb Day 2C Day 8 Day 15 Day 22
Blank liposomes 1.83+0.20d 1.02+0.19 1.27+0.06 1.11+0.09
2 Free deoxorubicin 0.43+0.08 0.71+0.14 1.10+0.15 1.26+0.19
Liposomal
doxorubicine 0.08+0.02 0.18+0.05 0.78+0.17 1.21+0.22
Blank liposomes 1.38+0.41 1.33+0.22 1.52+0.07 1.34+0.43
3 Free doxorubicin 0.13+0.02 0.15+0.02 0.66+0.20 1.29+0.40
Liposomal
doxorubicin 0.08+0.01 0.25+0.07 1.99+0.13 1.65+0.30
Blank liposomes 1.05+0.04 0.86+0.10 0.89+0.21 0.93+0.04
4 Free doxorubicin 0.06+0.02 0.09+0.06 0.09+0.005 0.72+0.03
Liposomal
doxorubicin 0.04+0.01 0.15+0.01 0.80+0.20 0.61 +0.10
aIndex is counts of experimental animals divided by mean counts of saline-treated control
animals; bNumber of weekly injections of indicated treatment; cDays are counted from the
time of last drug treatment; dMean proliferative index+s.d.: 3-4 animals per group; CItalicised values for free doxorubicin (or liposomal drug) are significantly lower than
liposomal drug (or free doxorubicin) by + test at P<0.05.
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Table III Mouse IgG levels (mgdlP) following chronic treatment with free or liposomal
doxorubicin
Drug coursesa Day lb Day 8 Day 15 Day 22
Blank liposomes 210C 170 210 250
3 Free doxorubicin 110 110 110 135
Liposomal
doxorubicin 100 138 110 180
Saline 170 170 170 250
Blank liposomes 250 390 450 335
4 Free doxorubicin 135 135 180 180
Liposomal
doxorubicin 250 180 135 135
Saline 335 450 335 335
aNumber of weekly injections of indicated treatment; bDays are counted from the time of
last drug treatment; cValues are ofpooled sera from 3-4 mice.
the results are presented in Table III. The saline
control mice ranged in total IgG levels from 180 to
250mgdl-1 in three dose groups whereas they
ranged from 335-450mgdl-1 in four dose groups.
The mice treated with 3 or 4 doses of free or
entrapped doxorubicin comparably had depressed
IgG levels and this may correspond to the
depressed lipopolysaccharide response also noted.
Discussion
The present study was undertaken to evaluate the
role of chronic administration of free doxorubicin
and doxorubicin entrapped in cardiolipin liposomes
on the suppression of immunity, since liposomal
drug is preferentially concentrated in spleen and
liver (Rahman et al., 1984; 1985; 1986; Juliano et
al., 1978; Forssen & Tokes, 1979). Previous studies
have shown that i.v. administration of doxorubicin
depresses the synthesis of circulating antibodies,
haemogglutinin and haemolysin. Furthermore, the
immunodepressive action of doxorubicin was shown
to be dose-dependent (Isetta et al., 1971;
Montovani et al., 1979). Since the participating host
defence mechanisms may influence the antitumor
activity of cancer chemotherapeutic agents, the
exaggerated concentration of doxorubicin in spleen
when administered entrapped in liposome may
adversely effect the therapeutic response of the
drug. Recently, we have demonstrated (Rahman et
al., 1986) that acute immunotoxicity of liposomal
doxorubicin was less profound than free drug.
Animals were administered with supralethal doses,
20mgkg-1, i.v. of free doxorubicin and
doxorubicin entrapped in cardiolipin liposomes for
generation of allospecific cytotoxicity and
demonstrated a significant decrease in the capacity
on day 15 with free drug. However, mice treated
with liposomal doxorubicin demonstrated similar
but less profound decrease in cytotoxic capacity. In
addition, the kinetics of depression of cytotoxicity
were altered; the decrease occurred earlier and was
of shorter duration with liposomal doxorubicin
than with free drug (Rahman et al., 1986).
The chronic administration of free and liposomal
drug resulted in the same sequence as observed in
the previous studies. Mice treated with two doses of
free doxorubicin, 7.5mgkg-' i.v., exhibited a
profound decrease to mount an allospecific
cytotoxicity on day 15, whereas liposomal drug
treated animals showed a less profound decrease in
this capacity at any time of evaluation (Figure 1).
With 3 and 4 doses of free drug and drug
entrapped in liposomes the maximum depression in
cytotoxic response was observed on day 8, but the
mice which received liposomal drug were fully
recovered by day 15 (Figures 2 and 3). In essence,
the depression in lytic activity for spleen in animals
treated with liposomal doxorubicin was less in
magnitude and of shorter duration than in animals
treated with free drug. The chronic administration
of blank liposomes did not cause any toxicity; on
the contrary, a stimulating effect was observed on
the generation of cytotoxicity with blank liposomes
at each time point of observation. However, blank
liposomes at four doses seemed to depress the
proliferative response of spleens against
concanavalin A in animals (Table I). In this
parameter of evaluation, two doses of liposomal
drug appeared to depress proliferative response on
day 8 more than free drug. However, three and
four doses of free doxorubicin depressed more
profoundly the proliferative response than
liposomal drug (Table I). The same pattern of
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observed in animals treated with free and liposomal
drug (Table II). IgG levels in the sera of those mice
(Table III), appeared to correlate with the response
to lipopolysaccharide.
Though the concentration of doxorubicin in
spleen was shown to be markedly increased
following administration of liposomal drug
(Rahman et al., 1986), it did not cause any greater
toxicity in animals than that of free drug according
to the immunologic parameters evaluated in this
study. On the other hand chronic administration of
free doxorubicin appeared to be more likely to
cause cumulative immunotoxicity than chronic
administration of liposomal drug. Though the
mechanisms of protection from this toxicity are not
fully understood, one of the possible explanations
for these observations may be that encapsulation of
the drug in cardiolipin liposomes localizes the
liposomes to particular population of immunocytes.
Alternatively, the rate of release of the drug may be
altered such that immunotoxicity is not enhanced.
Hence the location of liposomes or rate of release
of drug from this carrier may have an important
bearing on the effect and toxicity of the drug
(Juliano et al., 1983; Lopez-Berestein et al., 1984).
The potential clinical benefit of doxorubicin
entrapped in cardiolipin liposomes must be
evaluated in the light of the reduced acute and
chronic cardiotoxicity. Our studies demonstrate that
this modality of treatment completely prevents
drug-induced acute cardiotoxicity in mice (Rahman
et al., 1985) and chronic cardiotoxicity in beagle
dogs (Herman et al., 1983). In addition, we have
demonstrated enhanced therapeutic response with
liposomal drug in three murine tumour types
(Rahman et al., 1986a) which makes this modality
of treatment clinically important. In the present
study, we have used one-third higher doses of
liposomal doxorubicin than free drug to investigate
the immunocytotoxicity and proliferative responses.
However, even these enhanced drug doses in
liposomes fail to cause any greater toxicity than
free drug when immunologic parameters are
evaluated. Hence, the liposomal carrier system for
doxorubicin could be successfully exploited
clinically with enhanced therapeutic efficacy.
This work was supported by Bristol Myers Co., New
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